Anti‐RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications

Publisher Website
Google Scholar
Abstract
Focal bone loss around inflamed joints in patients with autoimmune disease, such as rheumatoid arthritis, remains a serious clinical problem. The recent elucidation of the RANK/RANK‐ligand/OPG pathway and its role as the final effector of osteoclastogenesis and bone resorption has brought a tremendous understanding of the pathophysiology of inflammatory bone loss, and has heightened expectation of a novel intervention. Here, we review the etiology of inflammatory bone loss, the RANK/RANK‐ligand/OPG pathway, and the clinical development of anti‐RANK‐ligand therapy. J. Cell. Biochem.